Medifast, Inc. 10-Q Summary: Quarter Ended March 31, 2005
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended March 31, 2005. Medifast, Inc. is a Delaware corporation engaged in the weight management industry, offering products and programs including the "Take Shape For Life" (TSFL) division and specialized nutritional solutions for conditions such as diabetes and arthritis.
Key Financial Metrics
| Metric | Q1 2005 | Q1 2004 |
|---|---|---|
| Revenue | $8,326,000 | $6,817,000 |
| Gross Profit | $6,253,000 | $5,467,000 |
| Gross Margin | 75.1% | 80.2% |
| Operating Income | $912,000 | $919,000 |
| Net Income | $507,000 | $647,000 |
| Diluted EPS | $0.04 | $0.05 |
| Cash from Operations | $337,000 | ($587,000) |
| Working Capital | $8,037,000 | $9,933,000 |
| Total Debt (Current + Long-term) | $5,613,000 | N/A |
| Cash and Equivalents | $916,000 | $1,539,000 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 22% ($1.5 million) driven by an effective multi-channel advertising campaign and the "Blueprint for Success" training program for TSFL Health Advisors.
- Margin Compression: Gross margin decreased from 80.2% to 75.1% as Cost of Sales rose 54% ($723,000), outpacing revenue growth.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 17% ($793,000) due to higher commissions, corporate infrastructure improvements, and start-up costs for new Hi-Energy Weight Control Clinics in Dallas.
- Profitability: Net income declined 22% to $507,000. Diluted EPS dropped to $0.04 from $0.05, primarily due to the dilution of 1.17 million shares from the conversion of Series B preferred stock.
- Liquidity: Working capital decreased by $1.9 million due to infrastructure investments and a reduction in deferred tax assets. Operating cash flow turned positive ($337,000) compared to a negative $587,000 in the prior year.
Outlook, Risks, and Unusual Items
- Management Commentary: Management attributes revenue growth to increased consumer awareness and the TSFL division's expansion. The company expects reduced seasonality in 2005 due to new product lines for specific health conditions.
- Strategic Changes: The joint venture with XL Health was terminated early in the quarter due to patient health incompatibilities; Medifast received 66,667 warrants as compensation. New leadership appointments include Michael S. McDevitt as President and Brendan N. Connors as VP of Finance.
- Research: Preliminary results from an 86-week Johns Hopkins study on Medifast Plus for Diabetics showed superior weight loss and compliance compared to ADA recommendations. Final results are expected in June 2005.
- Legal Risks:
- Class Action: A suit alleges Medifast bars violate Federal laws regarding Vitamin D3 content. The suit is stayed pending FDA clarification; management believes the claim lacks merit.
- Bankruptcy Dispute: A former consultant claims to have transferred stock to a third party to avoid bankruptcy proceedings. The Bankruptcy Trustee has declared the transfer invalid and is seeking the shares.
- Accounting Changes: The company is evaluating the impact of FAS 123R (Share-Based Payment), effective January 1, 2006, which may require expensing stock options.
Investor Verification Checklist
- Verify the sustainability of the 22% revenue growth given the 54% increase in Cost of Sales and the resulting margin compression.
- Monitor the cash burn rate associated with the new Hi-Energy Weight Control Clinics in Dallas, which currently lack significant revenue.
- Assess the impact of the 1.17 million share issuance on future earnings per share and dilution.
- Track the status of the Vitamin D3 litigation and the FDA's regulatory clarification.
- Confirm the final results of the Johns Hopkins diabetes study scheduled for June 2005 to validate the efficacy claims for the diabetic product line.